B
reathing is essential to life because it maintains blood oxygenation and eliminates carbon dioxide generated by metabolism. Many of the drugs required for anesthesia depress breathing, and significant effort is required by clinicians to minimize this adverse effect. Doxapram is a breathing stimulant drug that acts on the carotid body to promote ventilation in patients during and recovering from anesthesia (Fig. 1A) . 1 Doxapram antagonizes opioidand anesthetic-induced depression of breathing, expedites recovery from anesthesia, and decreases postoperative pulmonary complications. [2] [3] [4] [5] [6] [7] [8] TASK-1 and TASK-3 tandem pore potassium channel subunits provide a constitutive, acidic pH-and hypoxiainhibited potassium conductance, which regulate cellular resting membrane potential and excitability. [9] [10] [11] TASK-1 and TASK-3 subunits function as homodimers or coassociate and function as TASK-1/TASK-3 heterodimers. [12] [13] [14] I had previously determined that doxapram inhibits TASK-1, TASK-3, and TASK-1/TASK-3 heterodimer function with IC 50 s of 410 nM, 37 μM, and 9 μM, respectively, which are near or within doxapram's clinical concentration range. 15 The TASK-1/TASK-3 heterodimer provides the predominant hypoxia-sensitive background potassium conductance in rat carotid body type 1 glomus cells.
14 TASK-1 knockout mice and TASK-1/TASK-3 double knockout mice have impaired carotid body function, suggesting these channels also contribute to carotid body function. 16, 17 Finally, doxapram inhibits calcium-sensitive potassium channels (IC 50, approximately 13 μM), which may also be important in carotid body function. 18 Several potent and selective TASK-1 and TASK-3 potassium channel antagonists have been identified recently. Brendel et al. 19 made claims regarding a series of compounds, initially developed as Kv1.5 antagonists, to be BACKGROUND: TASK-1 and TASK-3 tandem pore potassium channel subunits provide a constitutive acidic pH-and hypoxia-inhibited potassium conductance. TASK channels are expressed in a number of tissues involved in regulation of breathing, and the TASK-1/TASK-3 heterodimer provides the predominant hypoxia-sensitive potassium conductance in carotid body type 1 glomus chemosensing cells. The carotid bodies have an important role in regulation of breathing. Doxapram is a potent TASK-1 and TASK-3 potassium channel antagonist and a carotid body and breathing stimulant. PK-THPP and A1899 are potent and selective TASK-1 and TASK-3 antagonists. I hypothesized PK-THPP and A1899 are, like doxapram, breathing stimulants. METHODS: I studied rat TASK-3 potassium channel function by Ussing chamber using Fischer rat thyroid monolayers. To quantify breathing effects, I studied male Sprague-Dawley rats spontaneously breathing 1.5% isoflurane in room air by noninvasive plethysmography and by arterial blood gas analysis. RESULTS: PK-THPP , A1899, and doxapram inhibit rat TASK-3 potassium channel function with IC 50 s of 42 nM (33-52), 1.6 μM (0.8-3.3), and 22 μM (18-28) (n = 4-6; 95% confidence limits). IV PK-THPP , A1899, and doxapram stimulated breathing by plethysmography with a peak change in minute ventilation relative to baseline of 84% ± 19% and 226% ± 56% (for PK-THPP at 0.5 and 5 mg/kg; mean ± SEM; n = 3-4; P < 0.05 and P < 0.001, respectively, relative to vehicle); 46% ± 2% and 236% ± 48% (for A1899 at 5 and 25 mg/kg; n = 3-4; P > 0.05 and P < 0.001, respectively); 103% ± 20% (for doxapram at 25 mg/kg; n = 4), and 33% ± 9% (for dimethylsulfoxide vehicle at 1 mL/kg; n = 4). PK-THPP and A1899, unlike doxapram, induced a profound and lasting respiratory alkalosis by arterial blood gas analysis. Thirty minutes after IV drug administration, I observed an arterial pH and carbon dioxide partial pressure of 7.62 ± 0.02 and 23 ± 0.8 mm Hg (for PK-THPP after 5 mg/kg; n = 4; P < 0.001 for both relative to vehicle), 7.49 ± 0.02 and 31 ± 2 mm Hg (for A1899 at 25 mg/kg; n = 6; P < 0.05 and 0.001, respectively), 7.43 ± 0.03 and 39 ± 4 mm Hg (for doxapram after 25 mg/kg; n = 4; P > 0.05 for both), and 7.38 ± 0.03 and 48 ± 4 mm Hg (for dimethylsulfoxide vehicle after 1 mL/kg; n = 3). CONCLUSIONS: PK-THPP and A1899 are potent rat TASK-3 antagonists and effective breathing stimulants. PK-THPP and A1899 effects on breathing were of greater magnitude and/or duration relative to that of doxapram. PK-THPP and A1899 or related compounds may have therapeutic potential for treating breathing disorders. (Anesth Analg 2013;116:810-6) potent TASK-1 and TASK-3 antagonists. Importantly, 2 of these compounds with IC 50 s of approximately 100 and 500 nM for TASK-1, like doxapram, stimulated breathing in rabbits and rats and augmented upper airway genioglossus electromyogram activity. More recently, 2 additional antagonists, A1899 and PK-THPP, have been reported. 20, 21 A1899 is an open channel blocker of TASK-1 and TASK-3 channels with IC 50 s of 7 and 70 nM, respectively, in Chinese hamster ovary cells (Fig. 1A) . 20 A1899 was developed as a Kv1.5 potassium channel antagonist. 22 PK-THPP is a propylketone (PK) derivative of tetrahydropyrido-pyrimidine (THPP) discovered using a high throughput strategy (Fig. 1A) . 21 PK-THPP inhibits TASK-1 and TASK-3 channels with IC 50 s of 300 and 35 nM, respectively, in human embryonic kidney cells. 21 The effects of PK-THPP and A1899 on breathing have not been reported.
Because doxapram and other TASK antagonists are ventilatory stimulants and because TASK channels are expressed in tissues involved in regulation of breathing, I hypothesized that PK-THPP and A1899 may stimulate breathing. To test this hypothesis, I first confirmed that PK-THPP and A1899 are potent TASK-3 potassium channel antagonists. I then used plethysmography and arterial blood gas analysis to quantify the breathing response of isoflurane-anesthetized rats after IV administration of PK-THPP or A1899.
METHODS

Molecular Biology and Electrophysiology
Rat TASK-3 cDNA was expressed from a pcDNA3.1/V5-His-TOPO-TA vector (Invitrogen, Carlsbad, CA). Fischer rat thyroid (FRT) epithelial cells were cultured and transfected as previously described. 23 FRT epithelial monolayers were studied 48 hours after transfection in an Ussing chamber (Physiologic Instruments, San Diego, CA). Junction potentials were offset before each experiment. A potassium gradient was applied across the monolayer. The apical solution contained (in millimolar): 135 NaCl, 1.2 MgCl 2 , 1.2 CaCl 2 , 10 HEPES, 10 dextrose, pH 7.4 with NaOH. The basolateral solution contained (in millimolar): 135 KCl, 1.2 MgCl 2 , 1.2 CaCl 2 , 10 HEPES, 10 Dextrose, pH 7.4 with KOH. MES (2-(N-morpholino)ethanesulfonic acid) was used in lieu of HEPES in pH 5.5 solutions. In all studies, the transepithelial voltage was clamped at 0 mV. A DVC-1000 amplifier (World Precision Instruments, Sarasota, FL) amplified the signal, which was digitized with no filtering at 10 Hz using a USB-6009 data acquisition board (National Instruments, Austin, TX) interfaced with an Apple Computer running Labview 8.5 software (National Instruments). Data were averaged every 1 second for analysis. Positive current indicates positive charge flowing in the basolateral to apical direction. Transepithelial voltage pulses +5 mV (1 second duration), referenced to the apical surface, were applied intermittently to assess transepithelial resistance and monolayer integrity. Air or air with isoflurane was continuously bubbled through apical and basolateral solutions. Isoflurane (Baxter Healthcare, Deerfield, IL) was applied and quantified as previously described. 23 All studies were conducted at room temperature (22°C-24°C).
Animal Studies
Studies were approved by the Massachusetts General Hospital Subcommittee on Research Animal Care, Boston, MA. Male Sprague-Dawley rats weighing 350 to 600 g were used and were obtained from Charles River Laboratories (Wilmington, MA) and housed in the Massachusetts General Hospital Center for Comparative Medicine Animal Facility. Femoral artery catheters were preimplanted by the vendor in some animals. In all studies, drugs were administered through a 24G lateral tail vein catheter and flushed in with 2 mL of saline. Rats in the PK-THPP, A1899, and dimethylsulfoxide (DMSO) vehicle only groups received 1 mL/kg IV DMSO.
Plethysmography
Rats were studied in a custom-built plethysmography chamber flushed with isoflurane 1.5% (Baxter Healthcare) in room air where they breathed spontaneously. All data were collected in the closed-chamber configuration, and solenoid valves (Cole Parmer, Vernon Hills, IL) (controlled via a Darlington power transistor array) were used to flush the chamber for 2 minutes every 2 minutes with isoflurane 1.5% in room air (at least 2 L/min flow) to remove rat-generated CO 2 . Chamber outflow was continuously sampled and analyzed using a Capnomac Ultima medical gas analyzer ANesthesiA & ANAlgesiA TASK Antagonists Stimulate Breathing (GE Healthcare, Buckinghamshire, UK) to quantify oxygen, CO 2 , and isoflurane levels in the chamber. The highest single CO 2 measurement in each study on chamber flushing ranged from 1.1% to 1.9% (1.4% ± 0.1%, mean ± SEM; n = 24). All plethysmography data acquisition and valve control were performed using LabView 8.5 software (National Instruments) run on an Apple computer interfaced with a USB-6009 data acquisition board (National Instruments). Chamber temperature and humidity were recorded automatically (DHT22, Aosong Electronics, Guangzhou, China), and rat temperature was continuously measured via a rectal thermistor. LabView 8.5 software used the rectal thermistor data to control a heat lamp (Powerswitch Tail II, powerswitchtail.com) to maintain the rodent temperature at 37°C. A differential pressure transducer and demodulator (Models CD15 and MP45-14-871; Validyne Engineering, Northridge, CA) were used to convert the chamber pressure to an analog signal. The signal was high-pass filtered at 15 seconds, acquired at 100 Hz, and analyzed in 4-second epochs using LabView 8.5 software to determine signal amplitude and frequency. The chamber was calibrated by injecting 0.5 mL of air through a Luer port with a rat-sized object occupying the chamber, and tidal volumes during intermittent chamber closure were estimated using methods described by Drorbaugh and Fenn. 24 
Blood Pressure and Blood Gas Analysis
Rats with femoral artery catheters were studied in a chamber continuously flushed with isoflurane 1.5% in room air where they breathed spontaneously. Mean arterial blood pressure was measured using a pressure transducer (TruWave, Edwards Life Sciences, Irvine, CA) interfaced with a custom-built amplifier (AD620 operational amplifier; Jameco Electronics, Belmont, CA). The signal was digitized at 1000 Hz using a USB-6009 data acquisition board (National Instruments) and analyzed in 4-second epochs. An arterial blood sample (0.3 mL) was drawn after 30 minutes of equilibration in isoflurane 1.5%, and 15 and 30 minutes after administration of PK-THPP, A1899, Doxapram, or DMSO (vehicle). Samples were analyzed promptly using CG4+ cartridges in a Vetscan iStat 1 (Abaxis, Union City, CA) blood gas analyzer.
Reagents
PK-THPP and A1899 were synthesized by Abjerjona Laboratories (Beverly, MA) to 98% purity using published methods. 21, 22 Structures were validated by high performance liquid chromatography/mass spectrometry and by 1 H-NMR. In all studies, PK-THPP and A1899 were solubilized in DMSO. Doxapram (Respiram) was from Modern Veterinary Therapeutics, LLC (Coral Gables, FL). All other reagents were from Fisher Scientific (Pittsburg, PA) or Sigma-Aldrich (St. Louis, MO), unless otherwise noted.
Statistical Analysis
Data were reported as mean ± SEM. Statistical analysis was done using Prism 5 software (GraphPad Software, Inc., La Jolla, CA). Multiple comparisons were performed using a 1-way or repeated measures analysis of variance followed by a Tukey-Kramer or Dunnett posttest; P < 0.05 indicates statistical significance. This analysis assumes comparisons were made between normally distributed data populations of equal variance and that all observations were independent of each other. Parameters derived from nonlinear regression were compared using an extra sum-of-squares F test.
RESULTS
PK-THPP and A1899 Effects on Rat TASK-3 Potassium Channel Function
Rat TASK-3 (rTASK-3) channels were transiently expressed in FRT monolayers, and their function studied by Ussing chamber. PK-THPP inhibited rTASK-3 function with an IC 50 of 42 nM (33-52, 95% confidence interval; n = 6) and 38 nM (27-52; n =3) (P = 0.6 by extra sum-of-squares F test) in the absence and presence of isoflurane (2.37 ± 0.1 mM), respectively (Fig. 1, B and C; isoflurane data not shown). A1899 inhibited rTASK-3 with an IC 50 of 1.6 μM (0.8-3.3; n = 4) (Fig. 1, B and C) . I have previously determined that DMSO (vehicle) up to 1% has minimal effect on rTASK-3 function. 23 PK-THPP and A1899 inhibition were difficult to washout (Fig. 1B) . Doxapram inhibited rTASK-3 with an IC 50 of 23 μM (18-28; n = 4) (Fig. 1, B and C).
Plethysmography Studies
PK-THPP, A1899, and doxapram increased minute ventilation by increasing tidal volume and breathing rate (Fig. 2) . PK-THPP effects, compared with that of A1899 and doxapram, occurred at lower doses. DMSO (1 mL/kg), the vehicle used for both agents caused a minor and shortlived increase in minute ventilation, as has been previously reported. 25 The peak normalized response of PK-THPP (0.5 and 5 mg/kg; 247% ± 17% and 326% ± 56%) and A1899 (25 mg/kg; 336% ± 48%) on minute ventilation were significantly different from that of doxapram (25 mg/kg; 203% ± 20%), A1899 (5 mg/kg; 146% ± 2%), and DMSO (1 mL/kg; 133% ± 9%) ( Fig. 2 ; P < 0.05 by 1-way analysis of variance with a Tukey-Kramer posttest).
Arterial Blood Gas and Arterial Blood Pressure Analysis
Both PK-THPP and A1899 induced a respiratory alkalosis and improved oxygenation 15 and 30 minutes after IV administration (Fig. 3) . Doxapram data merely trended toward alkalosis, and DMSO trended toward acidosis (Fig.  3) . A small increase in lactate levels was detected in A1899 and doxapram-treated rats (Fig. 3) . Neither PK-THPP nor DMSO had significant effects on normalized mean arterial blood pressure (Fig. 4) . A1899 had 1 data point that was increased, and doxapram caused an approximately 10% sustained increase in normalized mean arterial blood pressure (Fig. 4) .
DISCUSSION
In this study, I tested the hypothesis that 2 recently identified TASK potassium channel antagonists, PK-THPP and A1899, are breathing stimulants. I compared their effects with that of doxapram, a known breathing stimulant and TASK potassium channel antagonist. I confirmed that PK-THPP, A1899, and doxapram were potent rTASK-3 antagonists with IC 50 s of 42 nM, 1.6 μM, and 23 μM, respectively (Fig. 1) . Isoflurane had no effect on PK-THPP potency. Plethysmography studies demonstrated that PK-THPP, A1899, and doxapram stimulate breathing by increasing tidal volume and breathing rate (Fig. 2) . PK-THPP and A1899 induced a respiratory alkalosis and increased oxygenation for >30 minutes (Fig. 3) . The magnitude of PK-THPP and A1899 breathing effects exceeded that of doxapram. A1899 and doxapram caused a modest increase in lactate levels (Fig. 3D) . Unlike doxapram, which caused hypertension, PK-THPP and A1899 had limited effects on mean arterial blood pressure (Fig. 4) .
Breathing effects by plethysmography analysis were transient, yet arterial blood gas data showed a sustained effect (i.e., >30 minutes). I speculate the respiratory alkalosis, which evolves after drug administration, opposes the drug-induced increases in ventilation and likely explains this discrepancy. 26 The drug-induced increase in arterial oxygen pressure are likely due to increased alveolar oxygen pressure secondary to hypocapnia as predicted by the alveolar gas equation and/or due to diminished intrapulmonary shunting secondary to increased lung expansion/ recruitment during hyperventilation. 27 The origin of the lactic acidosis is unclear. Because the acidosis was not present in DMSO only-treated rats, it was unlikely from experimental artifact such as hypovolemia from repeated blood draws. It may have been due to altered tissue perfusion from hypocapnia-related vasoconstriction, impaired oxygen delivery by hemoglobin (i.e., the Bohr effect), the metabolic demands of breathing-related muscle activity, and/or some other unknown direct drug effect.
Anatomic Site(s) of Action
PK-THPP and A1899 directly stimulate breathing as demonstrated by the respiratory alkalosis on arterial blood gas analysis. Furthermore, blood pressure and 1 mL/kg) measured by plethysmography. Data were collected from spontaneously breathing rats inhaling 1.5% isoflurane in air. Data were normalized to the average minute ventilation, tidal volume, or breathing rate before study drug administration. n = 3 to 5 ± SEM for each; error bars are not visible when smaller than data point. Baseline minute ventilation, tidal volume, and breathing rate were 48 ± 3 mL/100 g/min, 0.7 ± 1 mL/100 g, and 67 ± 2 breathes/min, respectively (n = 24). B, Plethysmography signal tracings from a rat immediately before and immediately after receiving 5 mg/kg PK-THPP or 25 mg/kg A1899. Asterisks (*, **, and ***) indicate statistical significance (P < 0.05, P < 0.01, and P < 0.001, respectively) relative to the initial data point using repeated measures analysis of variance with a Dunnett posttest. The perforated line indicates zero relative pressure, with upward deflections indicating inspiration. The "L shaped" bars indicate time and calculated volume scaling. Figure 3 . IV PK-THPP and A1899 induce a respiratory alkalosis in spontaneously breathing rats. Arterial blood pH, carbon dioxide, oxygen, and lactate levels (A-D) from rats at baseline and 15 and 30 minutes after receiving IV PK-THPP (5 mg/kg), A1899 (25 mg/kg), doxapram (DOX) (25 mg/kg), and dimethylsulfoxide (DMSO) (vehicle only; 1 mL/kg). n = 3 to 4 ± SEM for each. Rats were breathing 1.5% isoflurane in room air. Asterisks (*, **, and ***) indicate statistical significance (P < 0.05, P < 0.01, and P < 0.001, respectively) by 1-way analysis of variance with a Dunnett posttest relative to the baseline values within each group.
ANesthesiA & ANAlgesiA TASK Antagonists Stimulate Breathing blood gas data demonstrate these compounds do not stimulate breathing through marked changes in blood pressure, blood pH, metabolism, or oxygenation. PK-THPP, A1899, and doxapram are structurally different molecules (Fig. 1A) . Therefore, they may or may not share a common site(s) or mechanism(s) of action. Because potassium permeability via potassium channel activity has a hyperpolarizing effect on neurons, a potassium channel antagonist will cause neuronal depolarization. This depolarization may decrease the threshold for neuronal activation and/or may be sufficient to cause direct neuronal activation. There are at least 4 general anatomic areas on which PK-THPP and A1899 may act: (1) the peripheral chemosensing cells of the carotid body, which stimulate breathing in response to hypoxia and acute acidemia; (2) the central chemosensing cells of the ventrolateral medulla, which stimulate breathing in response to cerebrospinal fluid acidification; (3) the central pattern generating brainstem neurons, which receive and integrate input from the chemosensing processes and which in summation provide the neuronal output to respiratory motor neurons; and/or (4) the motor neurons and muscles involved in breathing, which contract and relax in response to the brainstem neuronal output. TASK-1 and/or TASK-3 channels are expressed in each of these areas including motor neurons; only small levels of TASK-3 mRNA are present in rodent skeletal muscle. 10, 11, 14, [28] [29] [30] [31] [32] [33] [34] The carotid body is a likely target because TASK-1 and TASK-3 potassium channel function is prominent in carotid body chemosensing cells. Additionally, the carotid body is targeted by at least 2 breathing stimulants, doxapram and almitrine, and both drugs inhibit potassium channels. 1, [35] [36] [37] [38] Molecular Site of Action PK-THPP and A1899 were chosen for study because of their potent and selective inhibition of TASK-1 and TASK-3 potassium channels. Some or all of the effects on breathing may occur through TASK-1 and/or TASK-3 inhibition. However, I do not know the concentration of either compound at its site of action, and both PK-THPP and A1899 inhibit other potassium channels, albeit at markedly higher concentrations. Also, no one has reported the effects of PK-THPP and A1899 on the TASK-1/TASK-3 heterodimer. PK-THPP inhibits TREK-1, Kv1.5, hERG, and K ATP potassium channels with IC 50 s (in micromolar) of >10, approximately 5, >15, and >10, respectively.
21 A1899 inhibits TASK-2, TASK-4, TREK-1, TREK-2, TRAAK, THIK-1, TRESK, Kv1.1, and Kv1.5 potassium channels with IC 50 s (in micromolar) of 12.0, 8.1, 23.8, 8.4, >20, 2.2, 0.9, 2.7, and 1.2, respectively. 20, 22 Of these potassium channels, modulations of at least 2 alter breathing. Inhibition of THIK-1 function by isoflurane within brainstem chemosensing neurons may augment breathing during inhaled anesthesia. 39 TASK-2 activation during hypoxia may mediate central hypoxic ventilatory depression. 40 Other potassium channels relevant to breathing, but not specifically addressed in these panels, include the calcium-sensitive and rabbit Kv channels, which are inhibited by hypoxia to cause carotid body type 1 chemosensing cell activation. 41, 42 Of note, PK-THPP at 10 μM showed no activity against 100 different receptors in a PanLabs screen. 21 PK-THPP, A1899, and doxapram, though structurally different (Fig. 1A) , all share at least 2 properties: (1) potent TASK inhibition and (2) stimulation of breathing. Therefore, it is notable that the in vitro rank order potency for TASK-3 inhibition (PK-THPP > A1899 > doxapram) (Fig. 1) is preserved during in vivo breathing studies. PK-THPP is the most potent breathing stimulant and doxapram the least (Figs. 2 and 3) . Although my observations are consistent with TASK-3 as a molecular site of action, pharmacokinetic differences, which include differences in protein binding in the blood, cannot be excluded. I also did not study the effects on TASK-1, in vitro, which provide relatively small currents in my expression system. . IV PK-THPP and A1899 have minimal effect on arterial blood pressure in spontaneously breathing rats. Mean arterial blood pressure determined via femoral artery catheter at baseline (for 15 minutes) and for 30 minutes after receiving IV PK-THPP (5 mg/kg), A1899 (25 mg/kg), doxapram (25 mg/kg), and dimethylsulfoxide (DMSO) (vehicle; 1 mL/kg) are shown. Each data point is the average blood pressure data over a 5-minute time window normalized to average baseline mean blood pressure before study drug administration. Average mean arterial blood pressure for rats in these studies was 88 ± 1 mm Hg. n = 4 rats ± SEM for each data point. Asterisk (* and **) indicates significance (P < 0.05 and P < 0.01, respectively) relative to the 3 baseline data points by 1-way analysis of variance with a Dunnett posttest.
The TASK-3 IC 50 for PK-THPP determined in this study (42 nM) agrees well with that published by Coburn et al. 21 (35 nM). Similarly, the IC 50 for doxapram (23 μM) agrees well with our prior study (37 μM). 15 However, there was significant discrepancy between my A1899 IC 50 (1.6 μM) and that published by Streit et al. 20 (70 nM in Chinese hamster ovary cells and 318 nM in Xenopus oocytes). It may be due to differences in expression system or method of application, because Streit et al. 20 found large differences between Chinese hamster ovary cells studied by the whole cell patch clamp method (70 nM) and Xenopus oocytes studied by the 2-electrode voltage clamp method (318 nM). Also, A1899, which acts deep in the intracellular open pore, has the added constraint of gaining access to this site after extracellular application.
Streit et al. 20 identified the specific amino acids lining the intracellular pore vestibule of the TASK-1 open pore involved in A1899 blockade. These amino acids are highly conserved in TASK-3. Nothing, however, is known about the mechanism by which PK-THPP inhibits TASK-1 or TASK-3.
Effects of Isoflurane Anesthesia
All breathing studies were conducted in the presence of 1.5% (1 minimum alveolar concentration) inhaled isoflurane. Isoflurane was used because I was uncertain whether these compounds would induce convulsions or extreme agitation, particularly at higher dosages. In fact, no convulsions and no agitation were observed in any study subjects, even on recovery from isoflurane. Future studies will need to clarify whether PK-THPP and A1899 stimulate breathing in the absence of isoflurane. PK-THPP inhibitory potency for TASK-3 is unaffected by isoflurane.
TASK-1 and TASK-3 potassium channels are activated by halogenated volatile anesthetics, including isoflurane, and may contribute to volatile anesthetic effects including immobility and unconsciousness. [43] [44] [45] However, other than some transient movement on injection, which was also observed in the DMSO control group, I observed no overt signs of anesthesia reversal at 1.5% isoflurane.
Potential Clinical Utility
Doxapram has been useful in managing opioid and anesthetic depression of breathing and may shorten anesthetic recovery and minimize pulmonary complications, particularly in the obese. [5] [6] [7] [8] Doxapram is administered by continuous IV infusion due to rapid redistribution after injection, and this necessity likely limits its utility. PK-THPP and A1899 as breathing stimulants, relative to doxapram, are more potent and/or of longer duration. A more potent breathing stimulant requires administration of less drug, and therefore provides at least the potential to cause fewer undesired side effects (e.g., panic, agitation, hypertension, or fever as can be caused by doxapram). A longer acting drug, which does not require administration by continuous infusion, might find greater utility in treating drug-induced ventilatory depression beyond the perioperative environment and in treating chronic breathing disorders such as sleep apnea, obesity hypoventilation, or apnea of prematurity. E DISCLOSURES Name: Joseph F. Cotten, MD, PhD. Contribution: This author designed and conducted the study, analyzed the data, and prepared the manuscript. This manuscript was handled by: Marcel E. Durieux, MD, PhD.
